Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ID: DRG0MBZJF)
ADC Name
YL205
Synonyms
YL205
   Click to Show/Hide
Organization
MediLink Therapeutics (Originator)
Drug Status
Phase 1/2
Drug-to-Antibody Ratio
8
Structure
Antibody Name
Anti-NaPi2b mAb
  Antibody Info 
Antigen Name
Sodium-dependent phosphate transport protein 2B (SLC34A2)
  Antigen Info 
Payload Name
YL0010014
  Payload Info 
Payload Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Linker Name
VK*G-NHCH2-O linker
  Linker Info 
Conjugate Type
Random Cysteines
Combination Type
pelitecan
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
Disease Name Phase 1 Phase 2 Phase 3 Approved
Lung cancer
2 Trials
Clinical trial identifier
NCT06459973; CTR20241918
ChiCTR2400084741
Ovarian cancer
2 Trials
Clinical trial identifier
NCT06459973; CTR20241918
ChiCTR2400084741
Endometrial cancer
2 Trials
Clinical trial identifier
NCT06459973; CTR20241918
ChiCTR2400084741
Kidney cancer
2 Trials
Clinical trial identifier
NCT06459973; CTR20241918
ChiCTR2400084741
Unspecific solid tumor
2 Trials
Clinical trial identifier
NCT06459973; CTR20241918
ChiCTR2400084741
2027 Update
ADC-specific functional property
Bystander Killing Effect
Click To Hide/Show 1 ADC-specific functional property Data
Bystander Killing Effect Description Reference
yes
Additionally, YL205 exhibited strong potency, high internalization, potent cytotoxicity and bystander-mediated cell killing toward tumor cells.
[1]
References
Ref 1 Abstract 1894: Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors